GABAß-Agonistic Activity of Certain Baclofen Homologues

Mohamed I. Attia 1,2,*, Claus Herdeis 2,⁺ and Hans Bräuner-Osborne 3

1 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
2 Department of Pharmaceutical Chemistry, Institute of Pharmacy and Food Chemistry, Würzburg University, Am Hubland, Würzburg 97074, Germany
3 Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen DK-2100, Denmark

* Authors to whom correspondence should be addressed; E-Mails: mattia@ksu.edu.sa (M.I.A.); herdeis@pharmazie.uni-wuerzburg.de (C.H.); Tel.: +966-114677337 (M.I.A.); +49-893519594 (C.H.); Fax: +966-114676220 (M.I.A.); +49-8935731759 (C.H.).

Received: 12 July 2013; in revised form: 13 August 2013 / Accepted: 15 August 2013 / Published: 22 August 2013

Abstract: Baclofen (1) is a potent and selective agonist for bicuculline-insensitive GABAß receptors and is used clinically as an antispastic and muscle relaxant agent. In the search for new bioactive chemical entities that bind specifically to GABAß receptors, we report here the synthesis of certain baclofen homologues, namely (R,S)-5-amino-3-arylpentanoic acid hydrochlorides (R,S)-1a–h as well as (R,S)-5-amino-3-methylpentanoic acid [(RS)-1i] to be evaluated as GABAßR agonists. Compound 1a is an agonist to GABAß receptors with an EC₅₀ value of 46 μM on tsA201 cells transfected with GABAß₁b/GABAß₂/Gqz5, being the most active congener among all the synthesized compounds.

Keywords: GABA; synthesis; baclofen homologues; GABAß receptor agonists; pharmacological evaluation

1. Introduction

4-Aminobutanoic acid (GABA) is the well-known inhibitory neurotransmitter in the mammalian central nervous system where it exerts its effects through ionotropic (GABAₐC) receptors and metabotropic (GABAß) receptors [1]. Cloning and photoaffinity labeling experiments of the GABAß
receptor demonstrated two isoforms, designated GABA\textsubscript{B}1a and GABA\textsubscript{B}1b which dimerize with the GABA\textsubscript{B}2 receptor subunit to produce functionally active GABA\textsubscript{B} receptors [2]. 4-Amino-3-(4-chlorophenyl)butanoic acid (baclofen, \textbf{1}, Figure 1) is the classical GABA\textsubscript{B} agonist and interacts with GABA\textsubscript{B} receptors stereospecifically. The GABA\textsubscript{B} agonistic activity of racemic baclofen is known to reside primarily in the \textit{R}-(−)-enantiomer [3]. (\textit{R},\textit{S})-Baclofen (\textbf{1}) is used clinically for the treatment of spasticity associated with brain and spinal cord injuries [4], drug addiction and alcoholism [5], gastroesophageal reflux disease (GERD) [6], cancer pain [7] and overactive bladder [8]. Recently, \textit{R}-(−)-baclofen is under development for the treatment of behavioral symptoms of Fragile X Disorder [9].

(\textit{R})-5-Amino-3-(4-chlorophenyl)pentanoic acid (\textbf{2}), the homologue of baclofen (\textbf{1}), has been shown to exhibit a quite remarkable functional pharmacological profile in guinea pig ileum as compared to that of baclofen [10]. On the other hand, the homologue, (\textit{R},\textit{S})-5-amino-2-(4-chlorophenyl)pentanoic acid (\textbf{3}), does not interact detectably with GABA\textsubscript{B} receptors [11]. Moreover, 5-aminopentanoic acid (DAVA, \textbf{4}) is a nonselective GABA\textsubscript{B} antagonist [12]. Using baclofen (\textbf{1}) and DAVA (\textbf{4}) as two GABA\textsubscript{B} receptor prototypic ligands, a number of structural hybrids, namely (\textit{R},\textit{S})-5-amino-3-arylpentanoic acid hydrochlorides (\textit{RS})-\textbf{1a–h} (Figure 1), containing scaffolds of compounds \textbf{2} and \textbf{4} were synthesized and pharmacologically characterized as GABA\textsubscript{B} agonists. The importance of the aromatic moiety on GABA\textsubscript{B} agonistic activity of compounds (\textit{RS})-\textbf{1a–h} was also addressed via the synthesis and pharmacological evaluation of their aliphatic analogue, compound \textbf{1i}.

\textbf{Figure 1.} Chemical structures of baclofen (\textbf{1}), (\textit{R})-homobaclofen (\textbf{2}), (\textit{RS})-5-amino-2-(4-chloro-phenyl)pentanoic acid (\textbf{3}), 5-aminopentanoic acid (DAVA, \textbf{4}) and the target compounds (\textit{RS})-\textbf{1a–i}.

\[\text{1a–h}: \text{R} = \text{aryl} \quad \text{1i}: \text{R} = \text{methyl}\]

2. Results and Discussion

2.1. Chemistry

An examination of the literature revealed that there are two common synthetic strategies, namely the Horner-Wadsworth-Emmons (HWE) reaction and Knoevenagel condensation, which can be used to prepare the intermediate cyano esters \textbf{3a–c}, \textbf{3e–h} and \textbf{5i}. Therefore, HWE was applied for preparation of both \textbf{3a–c} and \textbf{3e–h} while Knoevenagel condensation was adopted to get \textbf{5i}, depending on the commercial availability of their respective starting materials. Accordingly, an allylic bromination step was required jointly with the HWE reaction to prepare compounds \textbf{3e–h}, while only
the HWE reaction and Knoevenagel condensation were required to prepare the cyano esters 3a–c and 5i, respectively.

The synthetic pathways which were adopted to synthesize the target compounds 1a–i are illustrated in Schemes 1–3. Thus, 3-aryl-4-chloro-2-butenoic acid ethyl esters 4a–c have been successfully produced by applying the HWE reaction on substituted acetophenones 5a–c using triethyl phosphonoacetate and sodium hydride in 1,2 dimethoxyethane following the procedure cited by Wadsworth and Emmons [13] (Scheme 1). The $^{13}$C-NMR chemical shift differences between C-1, C-3 and in particular C-4 for the (E) and (Z)-isomers of 4a–c are consistent with the observed differences for (E) and (Z)-isomers mentioned by Allan and Tran [14]. It is noteworthy that substitution at the ortho position of the phenyl ring in 2-chloro-1-(2,4-dichlorophenyl)-1-ethanone (5b) increased the proportion of (E)-isomer in the produced diasteromeric mixture of 4-chloro-3-(2,4-dichlorophenyl)-2-butenoic acid ethyl ester (4b), which is in accordance with the findings of Jones and Maisey [15].

Scheme 1. Synthesis of the target compounds 1a–d.

| Compound Nos. | R       |
|---------------|---------|
| 5a, 4a, 3a, 2a, 1a | 4-Cl    |
| 5b, 4b, 3b, 2b, 1b | 2,4-Cl2 |
| 5c, 4c, 3c, 2c, 1c | 4-CH3   |
| 2d, 1d         | H       |

Reagents and conditions: (i) (EtO)$_2$POCH$_2$COOEt/NaH/dry 1,2-dimethoxyethane/50 °C/18 h; (ii) (C$_2$H$_5$)$_4$N CN/CH$_3$CN/50 °C/18 h; (iii) H$_2$/Pd/C or PtO$_2$/4 bar/95% C$_2$H$_5$OH/conc. HCl /25 °C/18 h; (iv) 5N HCl/reflux/4h.

3-Aryl-4-chloro-2-butenoic acid ethyl esters 4a–c (as diasteromeric mixtures) were subjected to a nucleophilic displacement of the halogen with potassium cyanide in aqueous ethanol to obtain 3-aryl-4-cyano-2-butenoic acid ethyl esters 3a–c via the trivial procedure mentioned by Ives and Sames [16]. Unfortunately, the starting materials decomposed and we did not obtain the anticipated compounds 3a–c in any detectable amounts. This troublesome nucleophilic substitution reaction was successfully achieved using a stoichiometric amount of 3-aryl-4-chloro-2-butenoic acid ethyl esters
4a–c (as diastereomeric mixtures) and tetraethylammonium cyanide (TEAC). The reaction mixture was stirred at 50 °C in acetonitrile for 18 h according to the reported procedure [17]. The crude compounds 3a–c were purified by column chromatography using the appropriate solvent system to afford mainly (E)-3a–c in 42%–66% yields. Use of a catalytic amount of TEAC instead of a stoichiometric amount to produce 3a–c led to a dramatic decrease in the yields.

(E)-3-Aryl-4-cyano-2-butenoic acid ethyl esters 3a–c are multifunctional molecules and we aimed to reduce selectively both nitrile and double bond functionalities without affecting the ester functionality to afford the title compounds (R,S)-5-amino-3-aryl-pentanoic acid hydrochlorides 1a–d. Catalytic hydrogenation is one of the most powerful methods in the arsenal of the synthetic medicinal chemistry facilitating the chemical synthesis of a myriad of bio-active molecules both in research laboratories and industrial settings. Accordingly, 3a–c were subjected to catalytic hydrogenation using a catalytic amount of PtO2 (for 3a and 3b) or 10% Pd/C (for 3c) and concentrated hydrochloric acid in 95% ethanol on a Parr shaker apparatus under 4 bar of H2 for 18 h at room temperature to give (R,S)-5-amino-3-aryl-pentanoic acid ethyl ester hydrochlorides 2a–c.

It is noteworthy that catalytic hydrogenation of (E)-4-cyano-3-(2,4-dichlorophenyl)-2-butenoic acid ethyl ester (3b) using 10% Pd/C was accompanied by dehalogenation to give (R,S)-5-amino-3-phenylpentanoic acid ethyl ester hydrochloride (2d).

Without further purification the ester functionality of (R,S)-5-amino-3-arylpentanoic acid ethyl ester hydrochlorides 2a–d was hydrolyzed by refluxing (R,S)-2a–d in 5 N hydrochloric acid for 4 h. The crude (R,S)-1a–d were recrystallized from the isopropanol to afford the target compounds (R,S)-1a–d in 69%–76% yields. The structures of 1a–d have been established through microanalytical, IR, 1H-NMR, 13C-NMR, and mass spectral data.

Synthesis of the title compounds 1e–h is portrayed in Scheme 2. The synthetic pathway was commenced with the preparation of (Z)-3-aryl-4-bromo-2-butenoic acid ethyl esters 4e–h. Chemoselective allylic bromination of 3-aryl-2-butenoic acid ethyl esters 5e–h (as diastereomeric mixtures) was accomplished by adopting Wohl-Ziegler bromination.

**Scheme 2.** Synthesis of the target compounds 1e–h.
Scheme 2. Cont.

| 1–6 | X         |
|-----|-----------|
| e   | 3,4-Cl₂   |
| f   | 4-F       |
| g   | 3-OCH₃    |
| h   | 4-OCH₃    |

Reagents and conditions: (i) (EtO₂)₂POCH₂COOEt/KO-Bu/dry THF/reflux/18h; (ii) NBS/benzoyl peroxide/CCl₄/reflux/24; (iii) (C₂H₅)₄NCN/CH₃CN/50 °C/18 h; (iv) H₂/Pd/C or PtO₂/4 bar/95% C₂H₅OH/conc. HCl/25 °C/18 h; (v) 5N HCl/reflux/4h.

Compounds 5e–h and a stoichiometric amount of N-bromosuccinimide (NBS) were refluxed in carbon tetrachloride and then a catalytic amount of dibenzoyl peroxide (DBP) was added to the reaction mixture according to the method advocated by Chiefari et al. [18] to afford (Z)-3-aryl-4-bromo-2-butenolic acid ethyl esters 4e–h in moderate yields. The isolated isomers of 4e–h were assigned to be (Z)-isomers based on their ¹H-NMR spectral data.

Elaboration of 4e–h to give 3e–h was conducted using the aforementioned procedure for preparation of 3a–c. Subsequently, 3e–h were transformed to the target compounds 1e–h by adopting the same reaction sequence which was previously described for the preparation of compounds 1a–d from 3a–c.

The synthetic plan for the preparation of (R,S)-5-amino-3-methylpentanoic acid (1i) is provided in Scheme 3. Thus, cyanoacetic acid (6i) was subjected to the Knoevenagel reaction using ethyl acetoacetate, ammonium acetate and acetic acid in dry benzene under reflux conditions.

Scheme 3. Synthesis of the target compound 1i.

Reagents and conditions: (i) 1N HCl/100 °C/1.5 h; (ii) Ethyl acetoacetate/ammonium acetate/acetic acid/benzene/reflux/8 h; (iii) H₂/Pd/C/conc. HCl/4bar/95% ethanol/25 °C/18 h; (iv) 5N HCl/reflux/4 h/reflux; (v) Benzyl chloroformate/4N NaOH/0 °C/0.5 h; (vi) H₂/Pd/C/4 bar/50% 2-propanol/25 °C/18 h.
The produced crude 4-cyano-3-methyl-2-butenoic acid ethyl ester (5i) was distilled (100–102 °C/5 mm) to afford the α,β-unsaturated diasteromeric mixture 5i with an E/Z ratio = 1.7 (lit. [19] = E/Z ratio = 1.5) as detected by 1H-NMR.

4-Cyano-3-methyl-2-butenoic acid ethyl ester (5i, as a diasteromeric mixture) was subjected to catalytic hydrogenation using 10% Pd/C and concentrated hydrochloric acid in 95% ethanol to afford (R,S)-5-amino-3-methylpentanoic acid ethyl ester hydrochloride (4i). Without further purification, the crude 4i was hydrolyzed by reflux in 5 N hydrochloric acid to give (R,S)-5-amino-3-methylpentanoic acid hydrochloride (3i). It has to be mentioned that our attempt to obtain compound 3i in a sufficient pure form by recrystallization was unsuccessful. Accordingly, the amino functionality of 3i was derivatized with a lipophilic moiety to facilitate its purification by a simple acid-base chemical treatment.

(RS)-5-Benzylxoycarbonylamino-3-methylpentanoic acid (2i) has been synthesized by adopting the trivial procedure for protecting the amino groups of amino acids [20]. The crude (R,S)-5-benzyloxycarbonylamino-3-methylpentanoic acid (2i) was subjected to catalytic hydrogenation to cleave the N-benzyloxycarbonyl protecting group. The crude (R,S)-5-amino-3-methylpentanoic acid (1i) was recrystallized from 2-propanol/water to give (R,S)-1i as a white powder (m.p. 164–165 °C; lit. [21], 133–135 °C) in 69% yield. The structure of (R,S)-1i has been established through microanalytical, IR, 1H- NMR, 13C-NMR, and mass spectral data.

2.2. GABA<sub>B</sub> Agonistic Activity

We have previously described a robust pharmacological assay of heterodimeric GABA<sub>B</sub>R1b/GABA<sub>B</sub>R2 receptors co-expressed with the chimeric G protein Gaq-z5 in tsA201 cells (a transformed HEK293 cell line). Co-expression of Gaq-z5 convert the endogenous coupling to the G<i>α</i><sub>i/o</sub> signaling pathway to the Gq pathway, which generally leads to more robust assays measured as increases in inositol phosphates or intracellular calcium levels [22]. We have previously shown that the pharmacological profiles of a range of standard agonists using this assay correlate well with other assays using either cell lines with recombinant receptor expression or tissues with endogenous GABA<sub>B</sub>R expression. Furthermore, we have shown that the GABA<sub>B</sub>R antagonists 2-OH-saclofen and CGP35348 can antagonize agonist responses in this assay [23,24]. Finally, like other groups [25], we have not found any pharmacological differences of orthosteric ligands between GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b subunits co-expressed with GABA<sub>B</sub>R2 using this assay [23]. The assay is thus suitable for characterization of orthosteric GABA<sub>B</sub>R ligands, and in the present study we have characterized the synthesized ligands on GABA<sub>B</sub>R1b/GABA<sub>B</sub>R2 receptors co-expressed with the chimeric G protein Gaq-z5 in tsA201 cells measuring responses as increases in intracellular calcium measured by the calcium sensitive fluorescent probe Fluo-4.

The GABA<sub>B</sub> agonistic activity of the synthesized compounds 1a–i is summarized in Table 1. Compounds 1a, 1e and 1f are active as GABA<sub>B</sub>R agonists (EC<sub>50</sub> value 46–170 μM, Figure 2) whereas compounds 1b, 1c, 1d, 1g, 1h and 1i (EC<sub>50</sub> > 300 μM) are considered inactive as GABA<sub>B</sub>R agonists in the GABA<sub>B</sub>R subtype used in our assay.
Table 1. GABAB agonistic activity of the target compounds 1a–i.

![Chemical structure](image.png)

| Compound No. | R          | EC50 (μM) | pEC50 ± SEM |
|--------------|------------|-----------|-------------|
| 1a           | 4-Cl-C6H5  | 46        | 4.34 ± 0.1  |
| 1b           | 2,4-Cl2-C6H3 | >300   | <3.52       |
| 1c           | 4-CH3-C6H4 | >300      | <3.52       |
| 1d           | C6H5       | >300      | <3.52       |
| 1e           | 3,4-Cl2-C6H3 | 130    | 3.89 ± 0.1  |
| 1f           | 4-F-C6H4   | 170       | 3.77 ± 0.3  |
| 1g           | 3-OCH3-C6H4 | >300   | <3.52       |
| 1h           | 4-OCH3-C6H4 | >300   | <3.52       |
| 1i           | CH3        | >300      | <3.52       |
| (RS)-baclofen| -          | 5.8       | 5.24 ± 0.1  |

Figure 2. Concentration-response curves of compounds 1a, 1e, 1f and (RS)-baclofen on wild type GABAB1b co-expressed with GABAB2 and the chimeric G protein Gaq-z5. The curves are representative for the average pharmacological profile of the agonists. The Ca2+ measurement assays were performed as described in the materials and methods section.

Regarding the structure-activity relationship in the synthesized series 1a–i, it has to be mentioned that mono-substitution on the aromatic moiety attached to the 3-position of the DAVA backbone with a halogen, especially a para-chloro, is optimum for GABAB agonistic activity. The synthesized compounds which evoked GABAB agonistic activity have the following decreasing order of activity: 1a > 1e > 1f. On the other hand, substitution in the para-position of the aromatic moiety in the three position of the DAVA backbone with methoxy, methyl or no substitution led to loss of GABAB agonistic activity (EC50 > 300 μM). These results are comparable with the previously published results of GABAB agonists [26]. The lack of GABAB agonistic activity of compound 1b bearing a 2,4-dichloro aromatic moiety in the three position of the DAVA backbone could be attributed to steric
reasons which affect the interaction of 1b with the binding regions of GABA_{	ext{B}} receptors. In addition, replacement of the aryl moiety in the three position of the DAVA backbone with a methyl group, \textit{i.e.}, compound 1i, led to a loss of GABA_{	ext{B}}R agonistic activity. Compounds 1b, 1c, 1d, 1g, 1h and 1i which showed EC_{50} > 300 \mu M as GABA_{	ext{B}}R agonists were evaluated as GABA_{	ext{B}}R antagonists at 1 mM concentration against 10 \mu M GABA, but none of these compounds were effective as GABA_{	ext{B}}R antagonists.

3. Experimental

3.1. Chemistry

3.1.1. General

Melting points were determined using a capillary melting point apparatus (Gallenkamp, Sanyo) and are uncorrected. Infrared (IR) spectra were recorded as thin layer films (for oils) or as pellets (for solids) with BIO-RAD spectrometer and values are represented in cm\(^{-1}\). NMR (\textsuperscript{1}H-NMR and \textsuperscript{13}C-NMR) spectra were recorded on a Bruker AC 250 spectrometer (at 250 MHz for \textsuperscript{1}H-NMR and 63 MHz for \textsuperscript{13}C-NMR) and chemical shift values were recorded in ppm on the \(\delta\) scale. All samples were measured at room temperature. The \textsuperscript{1}H-NMR data are presented as follows: Chemical shifts, multiplicity, number of protons, assignment. Column chromatography was carried out on silica gel 60 (0.063–0.200 mm) obtained from Merck. Elemental analyses were performed by the microanalytical section of the Institute of Inorganic Chemistry, University of Würzburg, Würzburg, Germany.

3.1.2. General Procedure for the Preparation of 3-Aryl-4-chloro-2-butenoic Acid Ethyl Esters \textsuperscript{4a–c}

Triethyl phosphonoacetate (2.92 g, 13 mmol) was added dropwise to a cold (5–10 °C) stirred slurry of 60% sodium hydride (0.52 g, 13 mmol) in dry 1,2 dimethoxyethane (20 mL). After complete addition, the reaction mixture was stirred at ambient temperature for 30 min or until gas evolution ceased. A solution of the appropriate ketone \textsuperscript{5a–c} (10 mmol) in dry 1,2 dimethoxyethane (10 mL) was then added dropwise to the resulting solution. The reaction mixture was heated under stirring at 50 °C for 18 h. The reaction mixture was cooled to room temperature, poured into water (100 mL) and extracted with diethyl ether (3 \times 50 mL). The organic extract was dried (Na\textsubscript{2}SO\textsubscript{4}), filtered and evaporated under vacuum to afford viscous oils which were purified by column chromatography using petroleum ether (40–60 °C): Diethyl ether (9:1) to give compounds \textsuperscript{4a–c} in 40%–88% yields as pale yellow viscous oils.

\textit{(Z)-4-Chloro-3-(4-chlorophenyl)-2-butenoic acid ethyl ester} [(Z)-\textsuperscript{4a}]. Yield 80%; IR (neat): \(\nu\) (cm\(^{-1}\)) = 1711, 1628, 1492, 1176, 1160; \textsuperscript{1}H-NMR (CDCl\textsubscript{3}): \(\delta\) (ppm) = 1.15 (t, \(J = 7.33\) Hz, 3H, \textsuperscript{13}C–CH\textsubscript{2}–), 4.08 (q, \(J = 7.33\) Hz, 2H, –CH\textsubscript{2}–CH\textsubscript{3}), 4.88 (s, 2H, 4-H), 6.03 (s, 1H, 2-H), 7.20 (d, \(J_{\text{AB}} = 8.85\) Hz, 2H, H\textsubscript{arom.}), 7.30 (d, \(J_{\text{AB}} = 8.85\) Hz, 2H, H\textsubscript{arom.}); \textsuperscript{13}C-NMR (CDCl\textsubscript{3}): \(\delta\) (ppm) = 14.6 (CH\textsubscript{3}–CH\textsubscript{2}–), 39.4 (C-4), 61.1 (–CH\textsubscript{2}–CH\textsubscript{3}), 121.0 (C-2), 128.5, 129.4, 136.2, 137.0 (C\textsubscript{arom}), 151.8 (C-3), 165.7 (C-1).
(E)-4-Chloro-3-(4-chlorophenyl)-2-butenedioic acid ethyl ester [(E)-4a]. Yield 8%; IR (neat): \(\nu (\text{cm}^{-1}) = 1720, 1651, 1491, 1225, 1163\); \(^1\)H-NMR (CDCl\(_3\)): \(\delta (\text{ppm}) = 1.16 (t, J = 7.03 \text{ Hz, CH}_3–\text{CH}_2–), 4.07 (s, J = 7.03 \text{ Hz, } 2\text{H, } -\text{CH}_2–\text{CH}_3), 4.31 (d, J = 1.23 \text{ Hz, } 2\text{H, 4-H}), 6.28 (t, J = 1.23 \text{ Hz, } 1\text{H, 2-H}), 7.21 (d, \text{H}_{AB} = 8.55 \text{ Hz, } 2\text{H, H}_{arom.}), 7.39 (d, \text{H}_{AB} = 8.55 \text{ Hz, } 2\text{H, H}_{arom.}); \(^{13}\)C-NMR (CDCl\(_3\)): \(\delta (\text{ppm}) = 14.3 (\text{CH}_3–\text{CH}_2–), 48.7 (\text{C-4}), 121.5 (\text{C-2}), 128.8, 129.5, 135.0, 135.7 (\text{Carom.}), 151.3 (\text{C-3}), 165.5 (\text{C-1}).

(Z)-4-Chloro-3-(2,4-dichlorophenyl)-2-butenedioic acid ethyl ester [(Z)-4b]. Yield 48%; IR (neat): \(\nu (\text{cm}^{-1}) = 1707, 1641, 1581, 1436, 1341, 1186\); \(^1\)H-NMR (CDCl\(_3\)): \(\delta (\text{ppm}) = 1.11 (t, J = 7.03 \text{ Hz, } \text{CH}_3–\text{CH}_2–), 4.04 (q, J = 7.03 \text{ Hz, } 2\text{H, } -\text{CH}_2–\text{CH}_3), 4.79 (s, 2\text{H, 4-H}), 5.70 (s, 1\text{H, 2-H}), 6.98–7.22 (m, 3\text{H, H}_{arom.}); \(^{13}\)C-NMR (CDCl\(_3\)): \(\delta (\text{ppm}) = 14.6 (\text{CH}_3–\text{CH}_2–), 40.9 (\text{C-4}), 61.3 (\text{–C}_2\text{H}_2–\text{CH}_3), 124.6 (\text{C-2}), 127.6, 129.9, 130.0, 132.1, 135.7, 136.9, 151.9 (\text{C-3}), 165.2 (\text{C-1}).

(E)-4-Chloro-3-(2,4-dichlorophenyl)-2-butenedioic acid ethyl ester [(E)-4b]. Yield 34%; IR (neat): \(\nu (\text{cm}^{-1}) = 1720, 1585, 1473, 1226, 1164\); \(^1\)H-NMR (CDCl\(_3\)): \(\delta (\text{ppm}) = 1.14 (t, J = 7.03 \text{ Hz, } \text{CH}_3–\text{CH}_2–), 4.06 (q, J = 7.03 \text{ Hz, } 2\text{H, } -\text{CH}_2–\text{CH}_3), 4.31 (s, 2\text{H, 4-H}), 6.39 (t, J = 1.23 \text{ Hz, } 1\text{H, 2-H}), 7.13–7.48 (m, 3\text{H, H}_{arom.}); \(^{13}\)C-NMR (CDCl\(_3\)): \(\delta (\text{ppm}) = 14.3 (\text{CH}_3–\text{CH}_2–), 47.4 (\text{C-4}), 60.9 (\text{–C}_2\text{H}_2–\text{CH}_3), 123.4 (\text{C-2}), 127.4, 129.7, 130.9, 132.8, 134.8, 135.2, 149.3 (\text{C-3}), 164.8 (\text{C-1}).

(Z)-4-Chloro-3-(4-methylphenyl)-2-butenedioic acid ethyl ester [(Z)-4c]. Yield 36%; IR (neat): \(\nu (\text{cm}^{-1}) = 1710, 1626, 1609, 1173, 1158\); \(^1\)H-NMR (CDCl\(_3\)): \(\delta (\text{ppm}) = 1.37 (t, J = 7.03 \text{ Hz, } \text{CH}_3–\text{CH}_2–), 2.42 (s, 3\text{H, 4–CH}_3), 4.29 (s, 2\text{H, 4-H}), 5.12 (s, 2\text{H, 4-H}), 6.27 (s, 1\text{H, 2-H}), 7.26 (d, \text{H}_{AB} = 8.25 \text{ Hz, } 2\text{H, H}_{arom.}), 7.50 (d, \text{H}_{AB} = 8.25 \text{ Hz, } 2\text{H, H}_{arom.}); \(^{13}\)C-NMR (CDCl\(_3\)): \(\delta (\text{ppm}) = 14.6 (\text{CH}_3–\text{CH}_2–), 21.7 (4–\text{CH}_3), 39.5 (\text{C-4}), 60.9 (–\text{CH}_2–\text{CH}_3), 119.7 (\text{C-2}), 127.0, 129.9, 135.6, 140.4, 153.0 (\text{C-3}), 166.0 (\text{C-1}).

(E)-4-Chloro-3-(4-methylphenyl)-2-butenedioic acid ethyl ester [(E)-4c]. Yield 4%; IR (neat): \(\nu (\text{cm}^{-1}) = 1703, 1607, 1512, 1225, 1163\); \(^1\)H-NMR (CDCl\(_3\)): \(\delta (\text{ppm}) = 1.15 (t, J = 7.03 \text{ Hz, } \text{CH}_3–\text{CH}_2–), 2.40 (s, 3\text{H, 4–CH}_3), 4.07 (q, J = 7.03 \text{ Hz, } 2\text{H, } -\text{CH}_2–\text{CH}_3), 4.33 (d, J = 1.23 \text{ Hz, } 2\text{H, 4-H}), 6.26 (t, J = 1.23 \text{ Hz, } 1\text{H, 2-H}), 7.16 (d, \text{H}_{AB} = 8.25 \text{ Hz, } 2\text{H, H}_{arom.}), 7.23 (d, \text{H}_{AB} = 8.25 \text{ Hz, } 2\text{H, H}_{arom.}); \(^{13}\)C-NMR (CDCl\(_3\)): \(\delta (\text{ppm}) = 14.4 (\text{CH}_3–\text{CH}_2–), 21.8 (4–\text{CH}_3), 48.9 (\text{C-4}), 120.5 (\text{C-2}), 127.9, 129.3, 134.2, 138.9 (\text{C}_{arom.}), 152.6 (\text{C-3}), 165.9 (\text{C-1}).

3.1.3. General Procedure for the Preparation of 3-Aryl-2-butenedioic Acid Ethyl Esters 5e–h

To a cold (5–10 °C) solution of potassium \(\ell\)-butoxide (1.46 g, 13 mmol) in dry tetrahydrofuran (20 mL) was added dropwise triethyl phosphonoacetate (2.92 g, 13 mmol). The resulting solution was stirred at room temperature for 30 min. A solution of the appropriate ketone 6e–h (10 mmol) in dry tetrahydrofuran (10 mL) was added dropwise to the resulting solution. The reaction mixture was refluxed under stirring for 18 h. The reaction mixture was concentrated under vacuum, diluted with water (100 mL) and extracted with diethyl ether (3 × 50 mL). The combined organic extracts were dried (\(\text{Na}_2\text{SO}_4\)), filtered and evaporated under reduced pressure to give viscous oils which were purified by column chromatography using petroleum ether (40–60 °C): Diethyl ether (9:1) to afford compounds 5e–h in 75%–91% yields as pale yellow viscous oils.
(E)-3-(3,4-Dichlorophenyl)-2-butenoic acid ethyl ester [(E)-5e]. Yield 78%; IR (neat): ν (cm⁻¹) = 1711, 1630, 1469, 1277, 1169; ¹H-NMR (CDCl₃): δ (ppm) = 1.21 (t, J = 7.03 Hz, 3H, CH₃–CH₂–), 2.42 (d, J = 1.23 Hz, 3H, 4-H), 4.12 (q, J = 7.03 Hz, 2H, –CH₂–CH₃), 5.99 (q, J = 1.23 Hz, 1H, 2-H), 7.10–7.44 (m, 3H, Hₐrom.); ¹³C-NMR (CDCl₃): δ (ppm) = 14.7 (CH₃–CH₂–), 18.1 (C₄–CH₂–), 60.5 (–CH₂–CH₃), 118.8 (C-2), 125.9, 128.7, 130.8, 133.2, 133.4, 142.5 (Cₐrom.), 152.9 (C-3), 166.7 (C-1).

(Z)-3-(3,4-Dichlorophenyl)-2-butenoic acid ethyl ester [(Z)-5e]. Yield 6%; IR (neat): ν (cm⁻¹) = 1717, 1644, 1472, 1229, 1165; ¹H-NMR (CDCl₃): δ (ppm) = 1.21 (t, J = 7.03 Hz, 3H, CH₃–CH₂–), 2.17 (d, J = 1.53 Hz, 3H, 4-H), 4.07 (q, J = 7.00 Hz, 2H, –CH₂–CH₃), 5.96 (q, J = 1.53 Hz, 1H, 2-H), 7.05–7.46 (m, 3H, Hₐrom.). ¹³C-NMR (CDCl₃): δ (ppm) = 14.4 (CH₃–CH₂–), 27.3 (C₄–CH₂–), 119.4 (C-2), 126.9, 129.3, 130.3, 132.1, 132.5, 141.1 (Cₐrom.), 152.9 (C-3, C-5′).

(E)-3-(4-Fluorophenyl)-2-butenoic acid ethyl ester [(E)-5f]. Yield 69%; IR (neat): ν (cm⁻¹) = 1710, 1631, 1602, 1508, 1233, 1157; ¹H-NMR (CDCl₃): δ (ppm) = 1.32 (t, J = 7.03 Hz, 3H, CH₃–CH₂–), 2.57 (d, J = 1.23 Hz, 3H, 4-H), 4.22 (q, J = 7.03 Hz, 2H, –CH₂–CH₃), 6.10 (q, J = 1.23 Hz, 1H, 2-H), 7.02–7.11 (m, 2H, Hₐrom.), 7.43–7.49 (m, 2H, Hₐrom.). ¹³C-NMR (CDCl₃): δ (ppm) = 14.7 (CH₃–CH₂–), 60.3 (C₄–CH₂–), 115.8 (d, J_C-3′, F& C-5′, F = 21.99 Hz, C-3′ and C-5′), 117.5 (C-2), 128.5 (d, J_C-2′, F& C-6′, F = 7.64 Hz, C-2′ and C-6′), 138.6 (d, J_C-1′, F = 2.87 Hz, C-1′), 154.6 (C-3), 163.6 (d, J_C-4′, F = 249.45 Hz, C-4′), 167.1 (C-1).

(Z)-3-(4-Fluorophenyl)-2-butenoic acid ethyl ester [(Z)-5f]. Yield 10%; IR (neat): ν (cm⁻¹) = 1718, 1638, 1603, 1509, 1226, 1153; ¹H-NMR (CDCl₃): δ (ppm) = 1.00 (t, J = 7.00 Hz, 3H, CH₃–CH₂–), 2.05 (d, J = 1.53 Hz, 3H, 4-H), 3.89 (q, J = 7.00 Hz, 2H, –CH₂–CH₃), 5.79 (q, J = 1.53 Hz, 1H, 2-H), 6.86–6.97 (m, 2H, Hₐrom.), 7.04–7.12 (m, 2H, Hₐrom.). ¹³C-NMR (CDCl₃): δ (ppm) = 14.4 (CH₃–CH₂–), 60.2 (–CH₂–CH₃), 115.3 (d, J_C-3′, F& C-5′, F = 21.98 Hz, C-3′ and C-5′), 118.5 (C-2), 129.2 (d, J_C-2′, F& C-6′, F = 7.60 Hz, C-2′ and C-6′), 137.0 (d, J_C-1′, F = 3.82 Hz, C-1′), 154.7 (C-3), 162.8 (d, J_C-4′, F = 247.41 Hz, C-4′), 166.2 (C-1).

(E)-3-(3-Methoxyphenyl)-2-butenoic acid ethyl ester [(E)-5g]. Yield 82%; IR (neat): ν (cm⁻¹) = 1709, 1627, 1578, 1216, 1156; ¹H-NMR (CDCl₃): δ (ppm) = 1.35 (t, J = 7.03 Hz, 3H, CH₃–CH₂–), 2.59 (d, J = 1.23 Hz, 3H, 4-H), 3.85 (s, 3H, OCH₃), 4.25 (q, J = 7.03 Hz, 2H, –CH₂–CH₃), 6.16 (q, J = 1.23 Hz, 1H, 2-H), 6.19–7.34 (m, 4H, Hₐrom.). ¹³C-NMR (CDCl₃): δ (ppm) = 14.7 (CH₃–CH₂–), 55.7 (OCH₃), 60.3 (–CH₂–CH₃), 112.5 (C-2), 114.7, 117.7, 119.2, 129.9, 144.2 (Cₐrom.), 155.8 (C-3), 160.0 (Cₐrom.), 167.2 (C-1).
(E)-3-(4-Methoxyphenyl)-2-butenoic acid ethyl ester [(E)-5h] [29]. Yield 71%; IR (neat): ν (cm⁻¹) = 1707, 1603, 1512, 1250, 1153; ¹H-NMR (CDCl₃): δ (ppm) = 1.34 (t, J = 7.03 Hz, 3H, CH₃–CH₂–), 2.59 (d, J = 1.23 Hz, 3H, 4-H), 3.84 (s, 3H, OCH₃), 4.23 (q, J = 7.03 Hz, 2H, –CH₂–CH₃), 6.14 (q, J = 1.23 Hz, 1H, 2-H), 6.91 (d, JAB = 8.85 Hz, 2H, H arom.), 7.48 (d, JAB = 8.85 Hz, 2H, H arom.). ¹³C-NMR (CDCl₃): δ (ppm) = 14.8 (C₃H–CH₂–), 18.0 (C-4), 55.7 (OCH₃), 60.1 (–CH₂–CH₃), 114.2 (C arom.), 115.7 (C-2), 128.1, 134.7 (C arom.), 160.8 (C arom.), 167.5 (C-1).

(Z)-3-(4-Methoxyphenyl)-2-butenoic acid ethyl ester [(Z)-5h]. Yield 4%; IR (neat): ν (cm⁻¹) = 1711, 1606, 1511, 1229, 1156; ¹H-NMR (CDCl₃): δ (ppm) = 1.17 (t, J = 7.00 Hz, 3H, CH₃–CH₂–), 2.20 (d, J = 1.53 Hz, 3H, 4-H), 3.84 (s, 3H, OCH₃), 4.07 (q, J = 7.00 Hz, 2H, –CH₂–CH₃), 5.91 (q, J = 1.53 Hz, 1H, 2-H), 6.91 (d, JAB = 8.85 Hz, 2H, H arom.), 7.23 (d, JAB = 8.85 Hz, 2H, H arom.); ¹³C-NMR (CDCl₃): δ (ppm) = 14.5 (C₃H–CH₂–), 27.5 (C-4), 55.6 (OCH₃), 60.1 (–CH₂–CH₃), 113.6 (C arom.), 117.5 (C-2), 128.9, 133.1 (C arom.), 155.3 (C-3), 159.8 (C arom.), 166.5 (C-1).

3.1.4. General Procedure for the Preparation of (Z)-3-Aryl-4-bromo-2-butenoic Acid Ethyl Esters 4e–h

A mixture of 3-aryl-2-butenolic acid ethyl esters 5e–h (9 mmol) and N-bromosuccinimide (1.69 g, 10 mmol) was refluxed with stirring. Benzoyl peroxide (0.02 g) was added to the reaction mixture and refluxing was continued for further 24 h. The reaction mixture was chilled and the solid succinimide was filtered off. The filtrate was dried (Na₂SO₄), filtered and evaporated under reduced pressure to give viscous oils which were purified by column chromatography using petroleum ether (40–60 °C): Diethyl ether (9:1) to yield mainly (Z)-3-aryl-4-bromo-2-butenoic acid ethyl esters 4e–h in 59%–71% yields as light brown viscous oils.

(Z)-4-Bromo-3-(3,4-dichlorophenyl)-2-butenoic acid ethyl ester [(Z)-4e]. Yield 59% as light brown viscous oil; IR (neat): ν (cm⁻¹) = 1711, 1626, 1474, 1290, 1178; ¹H-NMR (CDCl₃): δ (ppm) = 1.36 (t, J = 7.03 Hz, 3H, CH₃–CH₂–), 4.29 (q, J = 7.03 Hz, 2H, –CH₂–CH₃), 4.93 (s, 2H, 4-H), 6.19 (s, 1H, 2-H), 7.38–7.65 (m, 3H, H arom.); ¹³C-NMR (CDCl₃): δ (ppm) = 14.6 (C₃H–CH₂–), 26.3 (C-4), 61.2 (–CH₂–CH₃), 121.4 (C-2), 126.3, 129.0, 131.2, 133.6, 134.3, 138.9 (C arom.), 151.1 (C-3), 165.5 (C-1).

(Z)-4-Bromo-3-(4-fluorophenyl)-2-butenoic acid ethyl ester [(Z)-4f] [27]. Yield 67% as light brown viscous oil; IR (neat): ν (cm⁻¹) = 1709, 1626, 1610, 1510, 1234, 1162; ¹H-NMR (CDCl₃): δ (ppm) = 1.36 (t, J = 7.03 Hz, 3H, CH₃–CH₂–), 4.29 (q, J = 7.03 Hz, 2H, –CH₂–CH₃), 4.98 (s, 2H, 4-H), 6.19 (s, 1H, 2-H), 7.04–7.17 (m, 2H, H arom.); ¹³C-NMR (CDCl₃): δ (ppm) = 14.6 (C₃H–CH₂–), 26.3 (C-4), 61.0 (–CH₂–CH₃), 116.3 (d, JC₃–F, F & C₅–F = 21.57 Hz, C-3 and C-5), 120.1 (C-2), 129.0 (d, JC₂–F & C₆–F = 8.30 Hz, C-2' and C-6'), 134.9 (d, JC₁–F = 3.43 Hz, C-1'), 152.5 (C-3), 163.9 (d, JC₄–F = 239.36 Hz, C-4'), 165.9 (C-1).

(Z)-4-Bromo-3-(3-methoxyphenyl)-2-butenoic acid ethyl ester [(Z)-4g] [30]. Yield 73% as light brown viscous oil; IR (neat): ν (cm⁻¹) = 1709, 1625, 1579, 1224, 1161; ¹H-NMR (CDCl₃): δ (ppm) = 1.37 (t, J = 7.00 Hz, 3H, CH₃–CH₂–), 3.87 (s, 3H, OCH₃), 4.27 (q, J = 7.00 Hz, 2H, –CH₂–CH₃), 4.98 (s, 2H, 4-H), 6.23 (s, 1H, 2-H), 6.96–7.39 (m, 4H, H arom.); ¹³C-NMR (CDCl₃): δ (ppm) = 14.6 (C₃H–CH₂–),
(Z)-4-Bromo-3-(4-methoxyphenyl)-2-butoenoic acid ethyl ester [(Z)-4h] [31]. Yield 71% as pale yellow solid m.p. 80–82 °C; IR (neat): ν (cm⁻¹) = 1701, 1603, 1512, 1250, 1169; ¹H NMR (CDCl₃): δ (ppm) = 1.36 (t, J = 7.03 Hz, 3H, CH₃–CH₂–), 3.86 (s, 3H, OCH₃), 4.28 (q, J = 7.03 Hz, 2H, –CH₂–CH₃), 5.01 (s, 2H, 4-H), 6.21 (s, 1H, 2-H), 6.96 (d, J_AB = 9.15 Hz, 2H, Harom.), 7.55 (d, J_AB = 9.15 Hz, 2H, Harom.). ¹³C-NMR (CDCl₃): δ (ppm) = 14.7 (C_H3–CH2–), 26.8 (C-4), 55.8 (OCH₃), 60.8 (–CH₂–CH₃), 118.1 (C-2), 114.6, 128.4, 130.8, 161.4 (C_arom.), 152.3 (C-3), 166.2 (C-1).

3.1.5. General Procedure for the Preparation of (E)-3-Aryl-4-cyano-2-butoenoic Acid Ethyl Esters 3a–c and 3e–h

A solution of tetraethylammonium cyanide (0.78 g, 5 mmol) in acetonitrile (5 mL) was added dropwise to a stirred solution of 3-aryl-4-chloro-2-butoenoic acid ethyl esters 4a–c and/or (Z)-3-aryl-4-bromo-2-butoenoic acid ethyl esters 4e–h (5 mmol) in acetonitrile (10 mL) under nitrogen atmosphere. After complete addition, the reaction mixture was heated at 50 °C for 18 h. The reaction mixture was cooled, diluted with diethyl ether (30 mL) and washed with water (3 × 20 mL). The organic layer was dried (Na₂SO₄) and evaporated under reduced pressure to give dark red viscous oils which were purified by column chromatography using petroleum ether (40–60°C): Diethyl ether (8:2) to afford mainly (E)-3-aryl-4-cyano-2-butoenoic acid ethyl esters 3a–c and/or 3e–h as pale yellow viscous oils in 42%–66% yields.

(E)-4-Cyano-3-(4-chlorophenyl)-2-butoenoic acid ethyl ester [(E)-3a] [32]. Yield 42%; IR (neat): ν (cm⁻¹) = 2217, 1731, 1591, 1493, 1176, 1162; ¹H NMR (CDCl₃): δ (ppm) = 1.21 (t, J = 7.03 Hz, 3H, CH₃–CH₂–), 3.88 (s, 2H, 4-H), 4.15 (q, J = 7.03 Hz, 2H, –CH₂–CH₃), 5.79 (s, 1H, 2-H), 7.39 (s, 4H, Harom.). ¹³C-NMR (CDCl₃): δ (ppm) = 14.4 (CH₃–CH₂–), 39.7 (C-4), 62.0 (CH₂–CH₃), 99.9 (C-2), 116.9 (C=N), 127.9, 129.9, 135.7, 137.1 (C_arom.), 154.9 (C-3), 168.8 (C-1).

(E)-4-Cyano-3-(2,4-dichloro-phenyl)-2-butoenoic acid ethyl ester [(E)-3b]. Yield 46%; IR (neat): ν (cm⁻¹) = 2223, 1733, 1585, 1472, 1180; ¹H NMR (CDCl₃): δ (ppm) = 1.26 (t, J = 7.03 Hz, 3H, CH₃–CH₂–), 3.93 (s, 2H, 4-H), 4.16 (q, J = 7.03 Hz, 2H, –CH₂–CH₃), 5.62 (s, 1H, 2-H), 7.26–7.49 (m, 3H, 3H, Harom.); ¹³C-NMR (CDCl₃): δ (ppm) = 14.4 (CH₃–CH₂–), 39.7 (C-4), 61.9 (CH₂–CH₃), 105.2 (C-2), 115.8 (C=Н), 127.9, 130.3, 131.8, 132.8, 134.4, 136.1 (C_arom.), 155.4 (C-3), 168.4 (C-1).

(E)-4-Cyano-3-(4-methyl-phenyl)-2-butoenoic acid ethyl ester [(E)-3c]. Yield 66%; IR (neat): ν (cm⁻¹) = 2214, 1733, 1603, 1314, 1175, 1159; ¹H NMR (CDCl₃): δ (ppm) = 1.22 (t, J = 7.03 Hz, 3H, CH₃–CH₂–), 2.40 (s, 3H, 4`-CH₃), 3.90 (s, 2H, 4-H), 4.15 (q, J = 7.03 Hz, 2H, –CH₂–CH₃), 5.78 (s, 1H, 2-H), 7.23 (d, J_AB = 8.23 Hz, 2H, Harom.), 7.38 (d, J_AB = 8.23 Hz, 2H, Harom.). ¹³C-NMR (CDCl₃): δ (ppm) = 14.4 (CH₃–CH₂–), 21.7 (4`-CH₃), 39.7 (C-4), 61.9 (–CH₂–CH₃), 98.3 (C-2), 117.5 (C=Н), 126.4, 130.1, 134.3, 141.4 (C_arom.), 155.9 (C-3), 169.1 (C-1).

(E)-4-Cyano-3-(3,4-dichlorophenyl)-2-butoenoic acid ethyl ester [(E)-3e]. Yield 44%; IR (neat): ν (cm⁻¹) = 2219, 1732, 1550, 1472, 1179; ¹H NMR (CDCl₃): δ (ppm) = 1.05 (t, J = 7.03 Hz, 3H,
CH$_3$–CH$_2$–), 3.68 (s, 2H, 4-H), 3.98 (q, $J$ = 7.03 Hz, 2H, –CH$_2$–CH$_3$), 5.61 (s, 1H, 2-H), 7.08–7.37 (m, 3H, H$_{arom}$); $^{13}$C-NMR (CDCl$_3$): $\delta$ (ppm) = 14.4 (CH$_3$–CH$_2$–), 39.6 (C-4), 62.2 (–CH$_2$–CH$_3$), 101.1 (C-2), 116.5 (C$\equiv$N), 125.8, 128.5, 131.4, 133.9, 135.2, 137.3, (C$_{arom}$), 153.9 (C-3), 168.5 (C-1).

(E)-4-Cyano-3-(4-fluorophenyl)-2-butenoic acid ethyl ester [(E)-3f]. Yield 48%; IR (neat): $\nu$ (cm$^{-1}$) = 2217, 1732, 1601, 1511, 1237, 1162; $^1$H-NMR (CDCl$_3$): $\delta$ (ppm) = 1.22 (t, $J$ = 7.00 Hz, 3H, CH$_3$–CH$_2$–), 3.89 (s, 2H, 4-H), 4.16 (q, $J$ = 7.00 Hz, 2H, –CH$_2$–CH$_3$), 5.76 (s, 1H, 2-H), 7.07–7.16 (m, 2H, H$_{arom}$), 7.43–7.51 (m, 2H, H$_{arom}$); $^{13}$C-NMR (CDCl$_3$): $\delta$ (ppm) = 14.4 (CH$_3$–CH$_2$–), 39.8 (C-4), 62.0 (–CH$_2$–CH$_3$), 99.4 (C-2), 116.5 (d, $J_{C-3'\& C-5'}$, F $= 21.95$ Hz, C-3’ and C-5’), 117.1 (C=O), 128.6 (d, $J_{C-2'\& C-6'}$, F $= 8.57$ Hz, C-2’ and C-6’), 133.5 (d, $J_{C-1'}$, F $= 3.82$ Hz, C-1’), 155.1 (C-3), 164.4 (d, $J_{C-4'}$, F $= 252.23$ Hz, C-4’), 168.9 (C-1).

(E)-4-Cyano-3-(3-methoxy-phenyl)-2-butenoic acid ethyl ester [(E)-3g]. Yield 53%; IR (neat): $\nu$ (cm$^{-1}$) = 2216, 1733, 1599, 1577, 1229, 1177; $^1$H-NMR (CDCl$_3$): $\delta$ (ppm) = 1.22 (t, $J$ = 7.03 Hz, 3H, CH$_3$–CH$_2$–), 3.84 (s, 3H, OCH$_3$), 3.89 (s, 2H, 4-H), 4.16 (q, $J$ = 7.03 Hz, 2H, –CH$_2$–CH$_3$), 5.79 (s, 1H, 2-H), 6.97–7.37 (m, 4H, H$_{arom}$); $^{13}$C-NMR (CDCl$_3$): $\delta$ (ppm) = 14.4 (CH$_3$–CH$_2$–), 39.8 (C-4), 55.8 (OCH$_3$), 61.9 (–CH$_2$–CH$_3$), 99.7 (C-2), 112.4, 116.2 (C$_{arom}$), 117.2 (C=O), 118.9, 130.5, 138.7 (C$_{arom}$), 156.2 (C-3), 160.3 (C$_{arom}$), 168.9 (C-1).

(E)-4-Cyano-3-(4-methoxy-phenyl)-2-butenoic acid ethyl ester [(E)-3h] [32]. Yield 45%; IR (neat): $\nu$ (cm$^{-1}$) = 2213, 1732, 1599, 1514, 1251, 1179; $^1$H-NMR (CDCl$_3$): $\delta$ (ppm) = 1.21 (t, $J$ = 7.03 Hz, 3H, CH$_3$–CH$_2$–), 3.84 (s, 3H, OCH$_3$), 3.88 (s, 2H, 4-H), 4.15 (q, $J$ = 7.03 Hz, 2H, –CH$_2$–CH$_3$), 5.72 (s, 1H, 2-H), 6.92 (d, $J_{AB} = 8.85$ Hz, 2H, H$_{arom}$), 7.43 (d, $J_{AB} = 8.85$ Hz, 2H, H$_{arom}$); $^{13}$C-NMR (CDCl$_3$): $\delta$ (ppm) = 14.4 (CH$_3$–CH$_2$–), 39.6 (C-4), 55.8 (OCH$_3$), 61.9 (–CH$_2$–CH$_3$), 96.9 (C-2), 117.7 (C=O), 114.8, 128.1, 129.4, 161.9 (C$_{arom}$), 169.2 (C-1).

3.1.6. General Procedure for the Preparation of (R,S)-5-Amino-3-arylpentanoic Acid Hydrochlorides 1a–h

To a solution of (E)-3-aryl-4-cyano-2-butenoic acid ethyl esters 3a–c and/or 3e–h (2 mmol) in 95% ethanol (10 mL) and concentrated hydrochloric acid (1 mL) was added PtO$_2$ (0.05 g) for compounds 3a, 3b, 3e and 3f or 10% Pd/C (0.10 g) for compounds 3b, 3c, 3g and 3h. The reaction mixture was hydrogenated on a Parr shaker apparatus under 4 bar of H$_2$ for 18 h at room temperature. The catalyst was removed by filtration and the solvent was evaporated under reduced pressure to give (R,S)-5-amino-3-arylpentanoic acid ethyl ester hydrochlorides 2a–h which were dissolved in 5 N hydrochloric acid (15 mL) and washed with diethyl ether (2 × 10 mL). Without further purification, the aqueous layer was refluxed with stirring for 4 h. The reaction mixture was evaporated under vacuum to give (R,S)-5-amino-3-arylpentanoic acid hydrochlorides 1a–h which were recrystallized from the isopropanol.

(R,S)-5-Amino-3-(4-chlorophenyl)pentanoic acid hydrochloride (1a). Yield 76% as white solid m.p. 201–203 °C; IR (neat): $\nu$ (cm$^{-1}$) = 3200–2727 and 1726; $^1$H-NMR (D$_2$O): $\delta$ (ppm) = 1.81–2.05 (m, 2H, 4-H), 2.50–2.87 (m, 4H, 2-H and 5-H), 2.99–3.12 (m, 1H, 3-H), 7.17 (d, $J_{AB} = 8.55$ Hz, 2H, H$_{arom}$), 7.26 (d, $J_{AB} = 8.55$ Hz, 2H, H$_{arom}$); $^{13}$C-NMR (D$_2$O): $\delta$ (ppm) = 33.2 (C-4), 38.0 (C-2), 39.1 (C-3), 41.1 (C-5), 129.2, 129.4, 132.7, 140.9 (C$_{arom}$), 176.6 (C-1); MS (EI), m/z (%): 209 (100), 181 (30), 138
Molecules 2013, 18 10279

(R,S)-5-Amino-3-(2,4-chlorophenyl)pentanoic acid hydrochloride (1b). Yield 70% as white solid m.p. 215–217 °C; IR (neat): v (cm⁻¹) = 3200–2700 and 1728; ¹H-NMR (D₂O): δ (ppm) = 1.87–2.12 (m, 2H, 4-H), 2.57–2.98 (m, 4H, 2-H and 5-H), 3.58–3.70 (m, 1H, 3-H), 7.20–7.32 (m, 3H, H_arom.); ¹³C-NMR (D₂O): δ (ppm) = 32.6 (C-4), 35.0 (C-2), 37.8 (C-3), 39.7 (C-5), 128.3, 129.3, 129.7, 133.1, 134.6, 138.5 (C_arom.), 176.3 (C-1); MS (EI), m/z (%): 243 (37), 208 (72), 172 (49), 97 (100), 43 (46); MS (CI), m/z (%): 261 [(100), M⁺ -1]; Anal. Calcd. for C₁₁H₁₄Cl₃NO₂: C 44.25, H 4.73, N 4.69; found C 44.10, H 4.76, N 4.79.

(R,S)-5-Amino-3-(4-methylphenyl)pentanoic acid hydrochloride (1c). Yield 78% as white solid m.p. 204–206 °C; IR (neat): v (cm⁻¹) = 3200-2720 and 1726; ¹H-NMR (D₂O): δ (ppm) = 1.80–2.03 (m, 2H, 4-H), 2.19 (s, 3H, 4’-CH₃), 2.50–2.86 (m, 4H, 2-H and 4-H), 2.96–3.08 (m, 1H, 3-H), 7.12 (s, 4H, H_arom.); ¹³C-NMR (D₂O): δ (ppm) = 20.5 (4’-CH₃), 33.3 (C-4), 38.1 (C-2), 39.3 (C-3), 41.3 (C-5), 127.8, 129.9, 137.8, 139.2 (C_arom.), 176.9 (C-1); MS (CI), m/z (%): 207 [(100), M⁺ ]; Anal. Calcd. for C₁₂H₁₈ClNO₂: C 59.14, H 7.44, N 5.75; found C 58.75, H 7.39, N 5.76.

(R,S)-5-Amino-3-phenylpentanoic acid hydrochloride (1d). Yield 69% as white solid m.p. 195–196 °C; IR (neat): v (cm⁻¹) = 3200–2690 and 1724; ¹H-NMR (D₂O): δ (ppm) = 1.83–2.06 (m, 2H, 4-H), 2.54–2.86 (m, 4H, 2-H and 5-H), 3.00–3.12 (m, 1H, 3-H), 7.12 (s, 4H, H_arom.); ¹³C-NMR (D₂O): δ (ppm) = 33.3 (C-4), 38.1 (C-2), 39.7 (C-3), 41.2 (C-5), 127.8, 129.4, 137.8, 142.3 (C_arom.), 176.9 (C-1); MS (EI), m/z (%): 194 [(10) M⁺ + 1], 175 (95), 104 (100), 91 (41), 43 (42); Anal. Calcd. for C₁₁H₁₆ClNO₂: C 57.52, H 7.02, N 6.09; found C 57.12, H 7.13, N 5.99.

(R,S)-5-Amino-3-(3,4-chlorophenyl)pentanoic acid hydrochloride (1e). Yield 80% as white solid m.p. 201–203 °C; IR (neat): v (cm⁻¹) = 3200–2700 and 1715; ¹H-NMR (D₂O): δ (ppm) = 1.81–2.05 (m, 2H, 4-H), 2.51–2.95 (m, 4H, 2-H and 5-H), 3.00–3.12 (m, 1H, 3-H), 7.09–7.39 (m, 3H, H_arom.); ¹³C-NMR (D₂O): δ (ppm) = 32.9 (C-4), 37.9 (C-2), 38.9 (C-3), 40.9 (C-5), 127.8, 129.7, 129.4, 142.3 (C_arom.), 176.9 (C-1); MS (CI), m/z (%): 261 [(100), M⁺ -1]; Anal. Calcd. for C₁₁H₁₄Cl₃NO₂: C 44.25, H 4.73, N 4.69; found C 44.04, H 4.99, N 4.79.

(R,S)-5-Amino-3-(4-fluorophenyl)pentanoic acid hydrochloride (1f). Yield 81% as white solid m.p. 208–210 °C; IR (neat): v (cm⁻¹) = 3200–2700 and 1724. ¹H-NMR (D₂O): δ (ppm) = 1.81–2.05 (m, 2H, 4-H), 2.49–2.87 (m, 4H, 2-H and 5-H), 3.00–3.12 (m, 1H, 3-H), 6.96–7.03 (m, 2H, H_arom.); ¹³C-NMR (D₂O): δ (ppm) = 32.9 (C-4), 37.9 (C-2), 38.9 (C-3), 40.9 (C-5), 115.9 (d, J_C-3`, F & C-5`, F= 21.38 Hz, C-3’ and C-5’), 129.5 (d, J_C-2’, F & C-6’, F = 8.17 Hz, C-2’ and C-6’), 137.9 (d, J_C-1’, F = 3.02 Hz, C-1’), 162.0 (d, J_C-4’, F = 242.87 Hz, C-4’), 176.8 (C-1); MS (CI), m/z (%): 211 [(100), M⁺ ]; Anal. Calcd. for C₁₁H₁₅ClFNO₂: C 53.34, H 6.10, N 5.66; found C 53.17, H 6.34, N 5.66.

(R,S)-5-Amino-3-(3-methoxyphenyl)pentanoic acid hydrochloride (1g). Yield 85% as pale yellow solid m.p. 182–184 °C; IR (neat): v (cm⁻¹) = 3200–2700 and 1724; ¹H-NMR (D₂O): δ (ppm) = 1.82–2.04 (m, 2H, 4-H), 2.52–2.87 (m, 4H, 2-H and 5-H), 2.98–3.10 (m, 1H, 3-H), 3.69 (s, 3H, OCH₃), 6.77–7.25
(m, 4H, Harom.); $^{13}\text{C}$-NMR (D$_2$O): $\delta$ (ppm) = 33.2 (C-4), 38.1 (C-2), 39.7 (C-3), 41.1 (C-5), 55.7 (OCH$_3$), 113.1, 113.6, 120.6, 130.6, 144.2, 159.6 (Carom.), 176.8 (C-1); MS (CI), m/z (%): 223 [(100), M$^+$]; Anal. Calcd. for C$_{12}$H$_{18}$ClNO$_3$: C 55.49, H 6.99, N 5.39; found C 55.20, H 7.01, N 5.33.

(R,S)-5-Amino-3-(4-methoxyphenyl)pentanoic acid hydrochloride (1h). Yield 76% as pale yellow solid m.p. 194–195 °C; (neat): $\nu$ (cm$^{-1}$) = 3200–2721 and 1724; 1H-NMR (D$_2$O): $\delta$ (ppm) = 1.79–2.03 (m, 2H, 4-H), 2.49–2.86 (m, 4H, 2-H and 5-H), 2.96–3.08 (m, 1H, 3-H), 3.68 (s, 3H, OCH$_3$), 6.86 (d, $J_{AB} = 8.85$ Hz, 2H, H arom.), 7.15 (d, $J_{AB} = 8.85$ Hz, 2H, Harom.). $^{13}$C-NMR (D$_2$O): $\delta$ (ppm) = 33.4 (C-4), 38.1 (C-2), 38.9 (C-3), 41.4 (C-5), 55.8 (OCH$_3$), 114.7, 129.0, 134.8, 158.2 (C arom.), 176.9 (C-1); MS (CI), m/z (%): 223 [(100), M$^+$]; Anal. Calcd. for C$_{12}$H$_{18}$ClNO$_3$: C 55.49, H 6.99, N 5.39; found C 55.23, H 7.07, N 5.35.

3.1.7. Synthesis of Cyanoacetic Acid (6i)

A mixture of ethyl cyanoacetate (7i, 10 g, 88 mmol) and 1 N hydrochloric acid (35 mL) was heated at 100 °C for 1.5 h. The reaction mixture was evaporated under reduced pressure to give 7.5 g (100%) of 6i as a colorless crystals m.p. 63–65 °C which was pure enough to be used in the next step without further purification. IR (neat): $\nu$ (cm$^{-1}$) = 3300–2973, 2269, 1725, 1388, 1183; 1H-NMR (DMSO-d$_6$): $\delta$ (ppm) = 3.28 (s, 2H, 2-H), 8.1–8.7 (br.s, 1H, COOH); 13C-NMR (DMSO-d$_6$): $\delta$ (ppm) = 25.5 (C-2), 116.3 (C≡N), 166.5 (C-1).

3.1.8. Synthesis of 4-Cyano-3-methyl-2-butenoic Acid Ethyl Ester (5i)

A mixture of cyanoacetic acid (6i, 4.51 g, 53 mmol), ethyl acetoacetate (6.51 g, 50 mmol), ammonium acetate (0.77 g, 10 mmol) and acetic acid (1.58 g, 1.5 mL, 26.3 mmol) in benzene (15 mL) was refluxed for 8 h using a Dean-Stark apparatus. The reaction mixture was evaporated under reduced pressure, water (10 mL) was added to the residue and extracted with diethyl ether (3 × 15 mL). The organic layer was separated, dried (Na$_2$SO$_4$) and evaporated under vacuum. The residue was distilled under vacuum to yield 5.2 g (68%) of 5i as a colorless oil b.p. 100–102 °C/5 mm (lit. [19] 130 °C/20 mm) with $E$/Z ratio = 1.7 as detected by 1H-NMR. IR (neat): $\nu$ (cm$^{-1}$) = 2221, 1733, 1636, 1175, 1161; 1H-NMR (CDCl$_3$): $\delta$ (ppm) = 1.24–1.31 (2 × t, 3H, CH$_3$–CH$_2$–), 2.01 [d, $J = 1.53$ Hz, 3H, (Z)-3-CH$_3$], 2.13 [d, $J = 0.93$ Hz, 3H, (E)-3-CH$_3$], 3.18 [d, $J = 0.90$ Hz, 2H, (E)-4-H], 3.42 [s, 2H, (Z)-4-H], 4.12–4.22 (2 × q, 2H, –CH$_2$–CH$_3$), 5.29–5.32 (m, 1H, 2-H); $^{13}$C-NMR (CDCl$_3$): $\delta$ (ppm) = 14.5 (CH$_3$–CH$_2$–), 21.7 [(E)-3-CH$_3$], 23.8 [(Z)-3-CH$_3$], 41.6 [(Z)-C-4], 43.9 [(E)-C-4], 61.8 (–CH$_2$–CH$_3$), 99.7 [(E)-C-2], 99.8 [(Z)-C-2], 116.6 [(Z)-C≡N], 116.7 [(E)-C≡N], 157.1 [(Z)-C-3], 157.2 [(E)-C-3], 168.9 [(Z)-C-1], 169.2 [(E)-C-1].

3.1.9. Synthesis of (R,S)-5-Benzylxoycarbonylamino-3-methylpentanoic Acid (2i)

To a solution of 4-cyano-3-methyl-2-butenoic acid ethyl ester (5i, 0.77 g, 5 mmol) in 95% ethanol (25 mL) was added concentrated hydrochloric acid (1 mL) and 10% Pd/C (0.26 g). The reaction mixture was hydrogenated on a Parr shaker apparatus under 4 bar of H$_2$ for 18 h at room temperature. The catalyst was removed by filtration and the solvent was evaporated under vacuum to give (RS)-5-amino-3-methyl-pentanoic acid ethyl ester hydrochloride (4i) which was dissolved in 5 N
hydrochloric acid (10 mL) and extracted with diethyl ether (3 × 10 mL). Without further purification the aqueous layer was refluxed under stirring for 4 h. The reaction mixture containing (RS)-5-amino-3-methylpentanoic acid hydrochloride (3i) was cooled (0–5 °C) and basified using 4 N sodium hydroxide solution (14 mL). To this basic solution was added simultaneously in portions and under cooling (0 °C) benzyl chloroformate (0.85 g, 5 mmol) and 4 N sodium hydroxide solution (1.25 mL) during 30 min. The reaction mixture was extracted with diethyl ether (3 × 10 mL), the aqueous layer was cooled (0–5 °C) and acidified using concentrated hydrochloric acid. The reaction mixture was extracted with diethyl ether (3 × 10 mL), dried (Na₂SO₄) and evaporated under reduced pressure to give 0.86 g (65%) of 2i as a viscous pale yellow oil which was used in the next step without further purification. IR (neat): \(\nu (\text{cm}^{-1}) = 3066–2588, 1699, 1528, 1454, 1523\); \(^1\)H-NMR (CDCl₃): \(\delta (\text{ppm}) = 1.02 (d, J = 6.1 \text{ Hz}, 3\text{H}, 3\text{-CH}_3), 1.39–1.50 (m, 1\text{H}, 4\text{-H}_a), 1.53–1.67 (m, 1\text{H}, 4\text{-H}_b), 1.98–2.15 (m, 1\text{H}, 3\text{-H}), 2.21–2.55 (m, 2\text{H}, 2\text{-H}), 3.25 (m, 2\text{H}, 5\text{-H}), 5.03 (\text{br.s} 1\text{H}, N\text{–H}), 5.13 (s, 2\text{H}, –CH₂–C₆H₅), 7.37 (s, 5\text{H}, H_{\text{arom.}}), 10.27 (\text{br.s}, 1\text{H}, COOH); \(^{13}\)C-NMR (CDCl₃): \(\delta (\text{ppm}) = 19.9 (3\text{-CH}_3), 27.9 (\text{C}-3), 36.8 (\text{C}-4), 39.3 (\text{C}-5), 41.7 (\text{C}-2), 67.2 (–CH₂–C₆H₅), 127.5, 128.6, 128.9, 136.9 (\text{C}_{\text{arom.}}), 157 (\text{O} = \text{C}–\text{N}–\text{H}), 178.8 (\text{C}-1).

3.1.10. Synthesis of (R,S)-5-Amino-3-methylpentanoic Acid (Ii)

To a solution of (R,S)-5-benzyloxycarbonylamino-3-methyl-pentanoic acid (2i, 0.53 g, 2 mmol) in 50% 2-propanol (10 mL) was added 10% Pd/C (0.85 g). The reaction mixture was hydrogenated on a Parr shaker apparatus under 4 bar of H₂ for 18 h at room temperature. The catalyst was removed by filtration and the solvent was evaporated under vacuum. The residue was recrystallized (2-propanol/water) to give 0.18 g (69%) of Ii as a white powder m.p. 164–165 °C (lit. [21] 133–135 °C). IR (neat): \(\nu (\text{cm}^{-1}) = 3019–2659, 1630, 1528, 1460, 1398\); \(^1\)H-NMR (D₂O): \(\delta (\text{ppm}) = 0.78 (d, J = 6.73 \text{ Hz}, 3\text{H}, 3\text{-CH}_3), 1.31–1.58 (m, 2\text{H}, 4\text{-H}), 1.71–1.85 (m, 1\text{H}, 3\text{-H}), 1.87–1.96 (m, 1\text{H}, 2\text{-H}_a), 2.02–2.10 (m, 1\text{H}, 2\text{-H}_b), 2.77–2.95 (m, 2\text{H}, 5\text{-H}); \(^{13}\)C-NMR (CDCl₃): \(\delta (\text{ppm}) = 19.1 (3\text{-CH}_3), 28.5 (\text{C}-3), 33.9 (\text{C}-4), 37.9 (\text{C}-5), 44.7 (\text{C}-2), 181.9 (\text{C}-1); \text{MS (Cl)}, \text{m/z (%)}: 149.1 [(100), M⁺+18]; \text{Anal. Calcd. for C}_6\text{H}_{13}\text{NO}_2: C 54.94, H 9.99, N 10.68; \text{found C 54.64, H 10.11, N 10.60.}

3.2. Pharmacological Evaluation

3.2.1. Materials

Culture media, serum and antibiotics were obtained from Invitrogen (Paisley, UK). The rat GABA₉R plasmids and the Gαq-z5 construct were generous gifts from Dr. Janet Clark (National Institute of Health, Bethesda, MD, USA) and Dr. Bruce Conklin (University of California, San Francisco, CA, USA). The tsA201 cells were a generous gift from Dr. Penelope S. V. Jones (University of California, San Diego, CA, USA).

3.2.2. Methods

TsA201 cells (a transformed human embryonic kidney (HEK) 293 cell line) [33] were maintained at 37 °C in a humidified 5% CO₂ incubator in Dulbecco’s modified Eagle medium (DMEM) supplemented with penicillin (100 U/mL), streptomycin (100 mg/mL) and 10% fetal calf serum. One million cells were split into a 10 cm tissue culture plate and transfected the following day with 0.7 μg
Molecules 2013, 18, 10282

GABA_B1b-pcDNA3.1, 3.5 μg GABA_B2-pcDNA3.1 and 0.7 μg Gaq-z5-pcDNA using SuperFect as a DNA carrier according to the protocol by the manufacturer (Qiagen, Hilden, Germany). The day after transfection, cells were split into one poly-D-lysine coated 96-well black-walled-clear-bottomed tissue culture plates in the same medium as mentioned above and incubated overnight. The following day the measurement of intracellular calcium was performed as follows. The media was exchanged with Hanks balanced saline solution containing 1 mM CaCl_2, 1 mM MgCl_2, 20 mM HEPES, 2.5 mM probencid and 4 μM Fluo-4AM (pH = 7.4). The cells were incubated for 1 h at 37 °C in a humidified 5% CO_2 incubator. Cells were then washed twice with the same buffer without Fluo-4AM and finally 100 μL of the buffer was left in the wells. The cell plate was then transferred to the NovoStar (BMG Labtechnologies, Offenburg, Germany) and the basal fluorescence level was adjusted to ~10,000 fluorescence units (FU) using excitation/emission wavelengths of 485–520 nm, respectively. Fluorescence readings were measured for 45 s after addition of ligand and response was calculated as peak response minus basal level. Inactive compounds were also tested as antagonists. Twenty min after application of ligand, 10 μM GABA was added to the well and fluorescence was measured as above.

3.2.3. Data Analysis

All data analysis has been carried out using GraphPad Prism version 6.0c for Mac OS X (GraphPad Software, San Diego, CA, USA). Concentration-response curves have been fitted by non-linear regression using the equation for sigmoidal concentration-response function:

\[ R = R_{\text{min}} + (R_{\text{max}} - R_{\text{min}})/(1 + 10^{(\log EC_{50} - X)}) \]

in which X is the logarithm of the agonist concentration, R is the response, R_{max} is the maximal response, R_{min} is the minimal response and EC_{50} is the concentration giving half maximum response. All experiments were performed in triplicate and the results are given as mean pEC_{50} ± S.E.M of 3–4 experiments.

4. Conclusions

Synthesis and GABA_B agonistic activity of certain amino acids 1a–i as homologues of the clinically used drug, baclofen (1), are reported. The presence of an aryl moiety in position three of the DAVA backbone is essential for GABA_B agonistic activity as replacement of this aryl moiety with a methyl group gave compound 1i which is devoid of GABA_B agonistic activity. Additionally, the substitution pattern of this aryl moiety plays an important role in the exhibited GABA_B agonistic activity. Thus, mono-substitution on the aromatic moiety attached to the three position of the DAVA backbone with a halogen, especially para-chloro (compound 1a), is optimum for GABA_B agonistic activity. Compound 1a showed GABA_B agonistic activity with EC_{50} = 46 μM, being the most active congener in the whole synthesized series.

Acknowledgments

The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for its funding of this research through the Research Group Project no. RGP-VPP-196.
Conflicts of Interest

The authors declare no conflict of interest.

References

1. Costantino, G.; Macchiarulo, A.; Guadix, A.E.; Pellicciari, R. QSAR and molecular modeling studies of baclofen analogues as GABA<sub>B</sub> agonists. Insights into the role of the aromatic moiety in GABA<sub>B</sub> binding and activation. J. Med. Chem. 2001, 44, 1827–1832.

2. Bernard, P.; Guedin, D.; Hibert, M. Molecular modeling of the GABA/GABA<sub>B</sub> receptor complex. J. Med. Chem. 2001, 44, 27–35.

3. Herdeis, C.; Hubmann, H.P. Synthesis of homochiral R-baclofen from S-glutamic acid. Tetrahedron: Asymmetry 1992, 3, 1213–1221.

4. Brogden, R.N.; Speight, T.M.; Avery, G.S. Baclofen: A preliminary report of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1974, 8, 1–14.

5. Tayacke, R.J.; Lingford-Hughes, A.; Reed, L.J.; Nutt, D.J. GABA<sub>B</sub> receptors in addiction and its treatment. Adv. Pharmacol. 2010, 58, 373–396.

6. Lidums, I.; Lehmann, A.; Checklin, H.; Dent, J.; Holloway, R.H. Control of transient lower esophageal sphincter relaxation. Gastroenterology 2000, 118, 7–13.

7. Yomiya, K.; Matsuo, N.; Tomiyasu, S.; Yoshimoto, T.; Tamaki, T.; Suzuki, T.; Matoba, M. Baclofen as an Adjuvant Analgesic for Cancer Pain. Am. J. Hosp. Palliat. Med. 2009, 26, 112–118.

8. Taylor, M.C.; Bates, C.P. A double-blind crossover trial of baclofen—a new treatment for the unstable bladder syndrome. Br. J. Urol. 1979, 51, 504–505.

9. Xu, F.; Peng, G.; Phan, T.; Dilip, U.; Chen, J.L.; Chernov-Rogan, T.; Zhang, X.; Grindstaff, K.; Annamalai, T.; Koller, K.; Gallop, M.A.; Wustrow, D.J. Discovery of a novel potent GABA<sub>B</sub> receptor agonist. Bioorg. Med. Chem. Lett. 2011, 21, 6582–6585.

10. Karla, R.; Ebert, B.; Thorkildsen, C.; Herdeis, C.; Johansen, T.N.; Nielsen, B.; Krosgsgaard-Larsen, P. Synthesis and pharmacology of baclofen homologues, 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorophenyl)pentanoic acid. J. Med. Chem. 1999, 42, 2053–2059.

11. Prager, R.H.; Schafer, K. Potential GABA<sub>B</sub> receptor antagonists. X. The synthesis of further analogues of baclofen, phaclofen and saclofen. Aust. J. Chem. 1997, 50, 813–823.

12. Muhyaddin, M.; Roberts, P.J.; Woodruff, G.N. Presynaptic γ-aminobutyric acid receptors in the rat anococcygeus muscle and their antagonism by 5-aminovaleric acid. Br. J. Pharmacol. 1982, 77, 163–168.

13. Wadsworth, W.S.; Emmons, W.D. The utility of phosphonate carbanions in olefin synthesis. J. Am. Chem. Soc. 1961, 83, 1733–1738.

14. Allan, R.D.; Tran, H., Synthesis of analogues of GABA. VII* (Z)- and (E)-4-Amino-3-(4-chlorophenyl)but-2-enoic acids as unsaturated baclofen derivatives. Aust. J. Chem. 1981, 34, 2641–2645.

15. Jones, G.; Maisey, R.F. Novel structural effects on the stereochemistry of the Wittig reaction with diethyl cyanomethylphosphonate. Chem. Commun. 1968, doi:10.1039/C19680000543.

16. Ives, D.J.G.; Sames, K. The determination of dissociation constants of monobasic acids. Part III. The strengths of some cyano-acids. J. Chem. Soc. 1943, doi:10.1039/JR9430000513.
17. Simchen, G.; Kobler, H. Synthese von Nitrilen mit Tetraalkylammoniumcyaniden. *Synthesis* **1975**, *9*, 605–607.
18. Chiefari, J.; Galanopoulos, S.; Janowski, W.K; Kerr, D.I.B.; Prager, R.H. The synthesis of phosphonobaclofen, an antagonist of baclofen. *Aust. J. Chem.* **1987**, *40*, 1511–1518.
19. Simchen, G. Eine neue Pyridinsynthese. *Chem. Ber.* **1970**, *103*, 389–397.
20. Boissonnas, R.A.; Preitner, G. Etude comparative de la scission de divers groupes de blocage de la fonction α-amino des acides amines. *Helv. Chim. Acta* **1953**, *36*, 875–886.
21. Wallach, O. Zur Kenntniss der Terpene und der ätherischen Oele. *Liebigs Ann. Chem.* **1900**, *312*, 171–210.
22. Conklin, B.R.; Farfel, Z.; Lustig, K.D.; Julius, D.; Bourne, H.R. Substitution of three amino acids switches receptor specificity of Gq to that of Gi. *Nature* **1993**, *363*, 274–276.
23. Bräuner-Osborne, H.; Krogsgaard-Larsen, P. Functional pharmacology of cloned heterodimeric GABA<sub>B</sub> receptors expressed in mammalian cells. *Br. J. Pharmacol.* **1999**, *128*, 1370–1374.
24. Jensen, A.A.; Madsen, B.E.; Krogsgaard-Larsen, P.; Bräuner-Osborne, H. Pharmacological characterization of homobaclofen on wild type and mutant GABA<sub>B</sub>1b receptors coexpressed with the GABA<sub>B</sub>2 receptor. *Eur. J. Pharmacol.* **2001**, *417*, 177–180.
25. Kaupmann, K.; Malitschek, B.; Schuler, V.; Heid, J.; Fröstl, W.; Beck, P.; Mosbacher, J.; Bischoff, S.; Kulik, A.; Shigemoto, R.; *et al.* GABA<sub>B</sub>-receptor subtypes assemble into functional heteromeric complexes. *Nature* **1998**, *396*, 683–687.
26. Berthelot, P.; Vaccher, V.; Flouquet, N.; Debaert, M.; Luyckx, M.; Brunet, C. 3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABA<sub>B</sub> receptor studies. *J. Med. Chem.* **1991**, *34*, 2557–2560.
27. Lampe, J.W.; Chou, Y.L.; Hanna, R.G.; Di Meo, S.V.; Erhardt, P.W.; Hagedorn, A.A.; Ingebretnsen, W.R.; Cantor, E. (Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase. *J. Med. Chem.* **1993**, *36*, 1041–1047.
28. Malamas, M.S.; Palka, C.L. New synthesis of isoxazolidines. *J. Heterocycl. Chem.* **1996**, *33*, 475–478.
29. Blankenstein, J.; Afaltz, A. A new class of modular phosphinite oxazoline ligands: Ir-catalyzed enantioselective hydrogenation of alkenes. *Angew. Chem. Int. Ed.* **2001**, *40*, 4445–4447.
30. Kagabu, S.; Kaku, I. Preparative method for 4-aryl and 4-alkyl-2-thiolenones. *Biosci. Biotech. Biochem.* **1993**, *57*, 1899–1901.
31. Islam, S.; Ueda, I. Synthesis of allylidenetriphenylphosphoranes and arsorsnes. *Dhaka Univ. J. Sci.* **1999**, *47*, 103–107.
32. Kubo, K.; Ito, N.; Souzu, I.; Isomura, Y.; Homma, H.; Murokami, M. Nitrogen-containing heterocyclic compounds. Brit. Pat. 1588166, 1981.
33. Chahine, M.; Bennett, P.B.; George Jr., A.L.; Horn, R. Functional expression and properties of the human skeletal muscle sodium channel. *Pfluegers Arch.* **1994**, *427*, 136–142.

*Sample Availability*: Samples of the compounds 1a–i are available from the authors.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).